新型β,β-桥连双卟啉的合成及其光敏活性研究

以1,6-二溴己烷为桥连试剂, 2-(1-羟基萘基)-5,10,15,20-四苯基卟啉及其Cu(Ⅱ), Ni(Ⅱ), Zn(Ⅱ)配合物为原料, 合成了4个新型β,β-桥连双卟啉. 以1,3-二苯基异苯并呋喃(DPBF)为猝灭剂, 测试了双卟啉及其Ni(Ⅱ), Zn(Ⅱ)配合物在光照条件下产生单线态氧的能力, 并研究了4个双卟啉化合物在光照和无光照条件下对pBR322质粒DNA的切割能力(用凝胶电泳)和对金黄色葡萄球菌(ATCC 25923)的光敏抑菌活性. 结果表明, 新型双卟啉光敏剂具有较好光敏活性, 产生的活性氧能有效杀灭金黄色葡萄球菌.     

新型β-双链桥连双卟啉的合成及光敏活性

设计合成了一种β-双链桥连双卟啉及其Cu(Ⅱ),Ni(Ⅱ),Zn(Ⅱ)配合物,通过1HNMR,MS,IR,UV和元素分析进行了表征.以1,3-二苯基异苯并呋喃(DPBF)为猝灭剂测试了β-双链双卟啉产生单线态氧的能力;通过DNA凝胶电泳比较了其对pBR322质粒DNA的光敏切割效果;采用紫外-可见光谱滴定法研究了其与小牛胸腺DNA的相互作用.实验结果表明,光敏剂β-双链双卟啉具有较强的产生单线态氧能力,β-双链桥连使双卟啉对pBR322质粒DNA具有较好的光敏切割效果,与DNA有较强的结合能力.     

和厚朴酚桥连卟啉光敏剂合成与结构表征

依次利用2-萘酚、1,6-二溴己烷、和厚朴酚,对2-硝基-5,10,15,20-四苯基卟啉及其金属配合物进行结构修饰,首次得到四对同分异构体桥连卟啉光敏剂,目标产物经UV-Vis,1H NMR,H-H COSY,IR,MS,元素分析等表征.以1,3-二苯基异苯并呋喃(DPBF)为猝灭剂测定了桥连卟啉产生单线态氧的能力;采用凝胶电泳和紫外-可见光谱滴定法,初步考察了化合物对pBR322质粒DNA的光敏切割能力及其与小牛胸腺DNA的作用模式.     

新型β-二酚卟啉光敏剂合成及其与DNA作用

以β-硝基卟啉为原料,分别与2,3-萘二酚或邻苯二酚直接反应,制备了6个新型β-二酚取代卟啉光敏药物,通过UV,~1H NMR,IR,MS,元素分析等手段对化合物进行了结构表征并初步探讨了反应机理.DNA凝胶电泳实验表明,该类光敏剂对pBR322质粒DNA具有很好的光敏切割作用,作为光敏剂或其前体具有很好的应用前景.     

β,β-偶氮桥连双卟啉的合成

用硼氢化钠/钯-碳还原2-硝基-5,10,15,20-四苯皋卟啉得到一种新型β,β-偶氮桥连双卟啉.通过UV-vis,1H NMR,IR,MS,拉曼光谱,元素分析等手段对化合物进行了结构表征.采用凝胶电泳法,初步考察了化合物在光照和无光照条件下对pBR322质粒DNA的切割能力.     

新型β-取代阳离子卟啉光敏剂合成及其与DNA相互作用

在5,10,15,20-四苯基卟啉及其金属配合物的β位引入阳离子型修饰基团溴化吡啶鎓盐, 得到β-[2-(6-吡啶溴化盐)己氧基]萘基-5,10,15,20-四苯基卟啉及其Cu(II), Ni(II), Zn(II)配合物. 通过IR, UV, ¹H NMR, MS以及元素分析对新化合物进行了结构表征. 作为光动力治疗光敏剂与pBR322质粒DNA的相互作用研究表明, 它们对DNA具有良好的光敏切割效果和结合能力, 通过与小牛胸腺DNA相互作用初步研究了它们与DNA的作用模式.     

meso-取代吡啶基卟啉的合成及结构表征

在癌症治疗中,卟啉化合物被用作光动力疗法(PDT)的光敏试剂.人们已经致力于制备新型卟啉化合物以用于癌症的光疗法[1,2]. 人工合成的含有吡啶盐、磺酸盐或羧酸盐等取代基的水溶性卟啉化合物能够在肿瘤组织上集聚[3].在寻找更有效的光敏剂的过程中,经过修饰的水溶性卟啉及其金属衍生物,由于它们能集聚在肿瘤组织并在光照下表现出较好的光敏活性,已引起了广泛关注.     

羰基四(对磺酸基苯基)卟啉钌(Ⅱ)的合成及光解水产氢的研究

金属卟啉在绿色植物的光合作用中起着重要的电子传递功能,在光解水产氢的研究中被用做光敏剂.在筛选金属卟啉光敏剂的研究中,通过改变卟啉环上的取代基和中心离子,将能改善其光敏性能.Okura等曾研究以羰基四苯基卟啉钌[Ru(CO)TPP]为光敏剂的光解水产氢体系,但由于Ru(CO)TPP不溶于水,故采用表面活性剂将其分散在水中,进行光敏效应的研究.我们合成了一种水溶性的钌卟啉化合物Ru(CO)TPPS,通过电子吸收光谱、红外光谱、核磁共振谱及元素分析等确定结构,并对Ru(CO)TPPS-K_2PtCl_6-TiCl_3复合光解水产氢体系进行了研究.实验结果表明,该体系的酸性水溶液在光照条件下,有较好的释氢性能和较高的转化数.     

β-氢醌-四(对羟基苯基)卟啉的合成及其抗肿瘤活性

合成并初步研究了新型β-取代卟啉光敏剂2-氢醌-5,10,15,20-四(4-羟基苯基)卟啉锌(II)(Zn(II)P)、2-氢醌-5,10,15,20-四(4-羟基苯基)卟啉铜(II)(Cu(II)P)的抗肿瘤活性。结果表明,2-氢醌-5,10,15,20-四(4-羟基苯基)卟啉锌(II)的合成总产率60%,该光敏剂对慢性骨髓性白血病肿瘤细胞(K562)具有很好的光敏毒性,Zn(II)P的浓度为320mmol/L时,就能抑制90%以上的白血病肿瘤细胞的生长。     

水溶性桥联双卟啉与DNA相互作用的研究

以4,4'-二羧酸-2,2'-联吡啶为桥联试剂, 合成了一种含8个阳离子的水溶性桥联双卟啉(PD). 以5,10,15,20-四(4-N-甲基吡啶盐)卟啉(H₂TMPyP)为参照物, 使用紫外-可见光谱、荧光光谱、圆二色谱研究了水溶性双卟啉与小牛胸腺DNA (CT DNA)的相互作用, 以溴化乙啶(EB)竞争法测定了PD与CT DNA的表观键合常数(K_app)为1.2×10⁶ L•mol^－1 (H₂TMPyP为6.9×10⁶ L•mol^－1), 并使用凝胶电泳研究了PD对pBR322质粒DNA的切割能力. 实验结果表明PD与CT DNA的作用方式是插入和外部结合的混合模式.     

Strategy for Tuning the Photophysical Properties of Photosensitizers for Use in Photodynamic Therapy

A novel approach for tuning spectral properties, as well as minimizing aggregation, in zinc porphyrin and zinc phthalocyanine‐based compounds is presented. Particular emphasis is placed on use of these compounds as photosensitizers in photodynamic therapy (PDT). To accomplish this aim, a bulky hydrophobic cation, trihexyltetradecylphosphonium, is paired with anionic porphyrin and phthalocyanine dyes to produce a group of uniform materials based on organic salts (GUMBOS) that absorb at longer wavelengths with high molar absorptivity and high photostability. Nanoparticles derived from these GUMBOS possess positively charged surfaces with high zeta potential values, which are highly desirable for PDT. Upon irradiation at longer wavelengths, these GUMBOS produced singlet oxygen with greater efficiency as compared to the respective parent dyes.     

阿糖胞苷金属卟啉衍生物的合成及光动力抗肿瘤活性

设计并合成了阿糖胞苷卟啉衍生物(AHP), 并通过金属插入反应获得了4种金属卟啉衍生物, 采用核磁共振、红外光谱、紫外-可见光谱和质谱等手段对化合物的结构进行了表征.光动力抗肿瘤活性实验结果表明, 含药浓度为25 μmol/L的ZnAHP经光照30 min后对人乳腺癌MCF-7细胞的光动力杀伤率平均达(45.86±8.20)%.     

Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy

Photodynamic therapy (PDT) is now a well-recognized modality for the treatment of cancer. While PDT has developed progressively over the last century, great advances have been observed in the field in recent years. The concept of dual selectivity of PDT agents is now widely accepted due to the relative specificity and selectivity of PDT along with the absence of harmful side effects often encountered with chemotherapy or radiotherapy. Traditionally, porphyrin-based photosensitizers have dominated the PDT field but these first generation photosensitizers have several disadvantages, with poor light absorption and cutaneous photosensitivity being the predominant side effects. As a result, the requirement for new photosensitizers, including second generation porphyrins and porphyrin derivatives as well as third generation photosensitizers has arisen, with the aim of alleviating the problems encountered with first generation porphyrins and improving the efficacy of PDT. The investigation of nonporphyrin photosensitizers for the development of novel PDT agents has been considerably less extensive than porphyrin-based compounds; however, structural modification of nonporphyrin photosensitizers has allowed for manipulation of the photochemotherapeutic properties. The aim of this review is to provide an insight into PDT photosensitizers clinically approved for application in oncology, as well as those which show significant potential in ongoing preclinical studies.     

Computational design of chlorin based photosensitizers with enhanced absorption properties

The porphyrin and chlorin parent compounds constitute the base of many potent photosensitizers aimed to be utilized in photodynamic therapy (PDT). However, the photosensitizers available on the market today are not ideal for use in PDT; many of them suffering from drawbacks such as long-lasting photosensitization or absorption at wavelengths below the optimal tissue penetration. This has emphasized the need of new photosensitizers with improved photodynamic properties. In the present study we have used density functional theory based methods to design new chlorin compounds with conjugated substituents such as vinyl groups and carboxylic acids, aiming for strong absorption in the therapeutic window of PDT. The specific substituent positions were found to have a significant effect on the spectra. A chlorin with four propenoic acids was able to red-shift the absorption the most compared with non-substituted chlorin, generating the red-most absorption at 755 nm, and with significantly enhanced oscillator strengths. The results from the present study constitute a useful starting point for further design of tetrapyrrole derivatives as improved photosensitizers.     

Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy

Photodynamic therapy (PDT) is a promising new treatment modality for several diseases, most notably cancer. In PDT, light, O2, and a photosensitizing drug are combined to produce a selective therapeutic effect. Lately, there has been active research on new photosensitizer candidates, because the most commonly used porphyrin photosensitizers are far from ideal with respect to PDT. Finding a suitable photosensitizer is crucial in improving the efficacy of PDT. Recent synthetic activity has created such a great number of potential photosensitizers for PDT that it is difficult to decide which ones are suitable for which pathological conditions, such as various cancer species. To facilitate the choice of photosensitizer, this review presents a thorough survey of the photophysical and chemical properties of the developed tetrapyrrolic photosensitizers. Special attention is paid to the singlet-oxygen yield (PhiDelta) of each photosensitizer, because it is one of the most important photodynamic parameters in PDT. Also, in the survey, emphasis is placed on those photosensitizers that can easily be prepared by partial syntheses starting from the abundant natural precursors, protoheme and the chlorophylls. Such emphasis is justified by economical and environmental reasons. Several of the most promising photosensitizer candidates are chlorins or bacteriochlorins. Consequently, chlorophyll-related chlorins, whose PhiDelta have been determined, are discussed in detail as potential photosensitizers for PDT. Finally, PDT is briefly discussed as a treatment modality, including its clinical aspects, light sources, targeting of the photosensitizer, and opportunities.     

Spectroscopic properties and photodynamic effects of new lipophilic porphyrin derivatives: efficacy, localisation and cell death pathways

Photodynamic therapy (PDT) and photodynamic diagnostics (PDD) of cancer are based on the use of non-toxic dyes (photosensitisers) in combination with harmless visible light. This paper reports physicochemical properties, cell uptake, localisation as well as photodynamic efficiency of two novel lipophilic porphyrin derivatives, suitable for use as PDT sensitisers. Both compounds are characterised by high quantum yield of singlet oxygen generation which was measured by time-resolved phosphorescence. Photodynamic in vitro studies were conducted on three cancer cell lines. Results of cell survival tests showed negligible dark cytotoxicity but high phototoxicity. The results also indicate that cell death is dependent on energy dose and time following light exposure. Using confocal laser scanning microscopy both compounds were found to localise in the cytoplasm around the nucleus of the tumour cells. The mode of cell death was evaluated based on the morphological changes after differential staining. In summary, good photostability, high quantum yield of singlet oxygen and biological effectiveness indicate that the examined lipophilic porphyrin derivatives offer quite interesting prospects of photodynamic therapy application.     

Porphyrin FRET acceptors for apoptosis induction and monitoring

Photodynamic therapy (PDT) stands to benefit from improved approaches to real-time treatment monitoring. One method is to use activatable photosensitizers that can both induce cell death (via singlet oxygen) and monitor it (via caspase detection). Here, we report porphyrins as caspase-responsive Forster Resonance Energy Transfer (FRET) acceptors to organic fluorophore donors. Compared to porphyrin FRET donor constructs, singlet oxygen generation was unquenched prior to caspase activation, resulting in more efficient photosensitization in HT-29 cancer cells. The donor 5-Carboxy-X-Rhodamine (Rox) formed a robust FRET pair with the pyropheophorbide (Pyro) acceptor. The large dynamic range of the construct enabled ratiometric imaging (with Rox excitation) of caspase activation in live, single cells following induction of cell death (with Pyro excitation) using a single agent. Quantitative, unquenched activatable photosensitizers (QUaPS) hold potential for new feedback-oriented PDT approaches.